Information Provided By: 
Fly News Breaks for January 18, 2017
NBIX
Jan 18, 2017 | 07:56 EDT
After a trial of Neurocrine's valbenazine for adult Tourette's failed to demonstrate statistically significant improvement on the primary endpoint, Piper Jaffray analyst Charles Duncan says he's nonetheless "encouraged" by the results. Specifically, the analyst thinks that the "safety, activity, and lack of study execution issues" were all positive. He sees "little if any read through" to an ongoing study of pediatric & adolescent Tourette's, and he recommends buying the stock on weakness.
News For NBIX From the Last 2 Days
